NCT05137886

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles. If PR or CR was obtained after salvage treatment, patients will receive GBM conditioning regimen followed by ASCT as consolidation therapy. High-risk R/R cHL patients will be treated with PD-1 inhibitor after ASCT for 1 year. The purpose of current study is to determine the clinical efficacy and safety of PD-1 inhibitor combined with decitabine followed by ASCT as second-line treatment in patients with relapsed or refractory classic Hodgkin's lymphoma.

Conditions

• Hodgkin Lymphoma, Adult
• Relapse
• Refractory Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	PD-1 inhibitor	decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-01-01
• Completion: 2025-01-01
• First posted: 2021-11-30
• Last updated: 2021-12-17

Locations

1 site across 1 country: China